Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 241

1.

Prevention of early postmenopausal bone loss with cyclical etidronate.

Adami S, Bruni V, Bianchini D, Becorpi A, Lombardi P, Campagnoli C, Ferrari A, Marchesoni T, Balena R.

J Endocrinol Invest. 2000 May;23(5):310-6.

PMID:
10882149
[PubMed - indexed for MEDLINE]
2.

The effects of cyclical etidronate on early postmenopausal bone loss: an open, randomized controlled study.

Heath DA, Bullivant BG, Boiven C, Balena R.

J Clin Densitom. 2000 Spring;3(1):27-33.

PMID:
10745299
[PubMed - indexed for MEDLINE]
3.

Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.

Fogelman I, Herd RJ, Blake GM, Balena R.

Calcif Tissue Int. 2000 May;66(5):348-54.

PMID:
10773104
[PubMed - indexed for MEDLINE]
4.

The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.

Herd RJ, Balena R, Blake GM, Ryan PJ, Fogelman I.

Am J Med. 1997 Aug;103(2):92-9.

PMID:
9274891
[PubMed - indexed for MEDLINE]
5.

Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.

Diamond T, McGuigan L, Barbagallo S, Bryant C.

Am J Med. 1995 May;98(5):459-63.

PMID:
7733124
[PubMed - indexed for MEDLINE]
6.

Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.

Struys A, Snelder AA, Mulder H.

Am J Med. 1995 Sep;99(3):235-42.

PMID:
7653482
[PubMed - indexed for MEDLINE]
8.

The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.

Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K.

Osteoporos Int. 1997;7(1):52-8.

PMID:
9102064
[PubMed - indexed for MEDLINE]
9.

Rates of bone loss in peri- and postmenopausal women: a 4 year, prospective, population-based study.

Young R, May H, Murphy S, Grey C, Compston JE.

Clin Sci (Lond). 1996 Sep;91(3):307-12.

PMID:
8869413
[PubMed - indexed for MEDLINE]
10.

Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.

Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, Nijs J, Raus J.

Ann Rheum Dis. 1998 Dec;57(12):724-7.

PMID:
10070271
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
[PubMed - indexed for MEDLINE]
12.

Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.

Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C.

Rev Rhum Engl Ed. 1999 Apr;66(4):214-9.

PMID:
10339777
[PubMed - indexed for MEDLINE]
13.

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH 3rd.

Am J Med. 1997 Dec;103(6):468-76. Erratum in: m J Med 1998 Jun;104(6):608.

PMID:
9428829
[PubMed - indexed for MEDLINE]
14.

Role of oral pamidronate in preventing bone loss in postmenopausal women.

Lees B, Garland SW, Walton C, Ross D, Whitehead MI, Stevenson JC.

Osteoporos Int. 1996;6(6):480-5.

PMID:
9116394
[PubMed - indexed for MEDLINE]
15.

Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.

Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K; Probone Study Group.

Osteoporos Int. 2002 Dec;13(12):937-47.

PMID:
12459936
[PubMed - indexed for MEDLINE]
16.

Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial.

Beardsworth SA, Kearney CE, Purdie DW.

Br J Obstet Gynaecol. 1999 Jul;106(7):678-83.

PMID:
10428524
[PubMed - indexed for MEDLINE]
17.

Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation.

Orme SM, Simpson M, Stewart SP, Oldroyd B, Westmacott CF, Smith MA, Belchetz PE.

Clin Endocrinol (Oxf). 1994 Aug;41(2):245-50.

PMID:
7923830
[PubMed - indexed for MEDLINE]
18.

A longitudinal study of supine lateral DXA of the lumbar spine: a comparison with posteroanterior spine, hip and total-body DXA.

Blake GM, Herd RJ, Fogelman I.

Osteoporos Int. 1996;6(6):462-70.

PMID:
9116392
[PubMed - indexed for MEDLINE]
19.

A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.

Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley MI, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GF, Laan RF, Brown J, Geusens P.

J Rheumatol. 2000 Oct;27(10):2424-31.

PMID:
11036840
[PubMed - indexed for MEDLINE]
20.

The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur.

Duan Y, Tabensky A, DeLuca V, Seeman E.

Bone. 1997 Nov;21(5):447-51.

PMID:
9356739
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk